# Legend Biotech

Source: https://onco.cc/companies/legend-biotech/  
OnCo record `legend-biotech` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Legend Biotech is the Chinese-origin developer of Carvykti, the most effective myeloma CAR-T, with J&J.

## Summary

Legend Biotech, based in Somerset, New Jersey, and Nanjing and listed as LEGN, is the Chinese-origin developer of Carvykti, or ciltacabtagene autoleucel, the most effective myeloma CAR-T, in partnership with Johnson & Johnson. Cilta-cel was proved in LEGEND-2, CARTITUDE-1 and CARTITUDE-4, and the company is developing solid-tumour CAR-Ts including LB1908 against Claudin 18.2 and a DLL3 programme, with Fangliang Zhang among the people linked. OnCo links it to multiple myeloma, to the cilta-cel drug record and to the Comprehensive Cancer Center Mainfranken. Whether Legend can take a solid-tumour CAR-T as far as its myeloma product is the open question. Ciltacabtagene autoleucel has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Somerset, NJ / Nanjing
- Type: cell-therapy
- Website: https://www.legendbiotech.com
- Ticker: LEGN

## Sources

- Official website: https://www.legendbiotech.com

## Connected records

- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- drugs: [Ciltacabtagene autoleucel](https://onco.cc/drugs/ciltacabtagene-autoleucel/)
- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- trials: [CARTITUDE-1](https://onco.cc/trials/cartitude-1/), [CARTITUDE-4](https://onco.cc/trials/cartitude-4/), [LEGEND-2](https://onco.cc/trials/legend-2/)
- people: [Fangliang (Frank) Zhang](https://onco.cc/people/zhang-fangliang/)
- key papers: [CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma](https://onco.cc/key-papers/paper-cartitude-1-cilta-cel-lancet-2021/), [CARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy](https://onco.cc/key-papers/paper-cartitude-4-cilta-cel-nejm-2023/)
- institutions: [Comprehensive Cancer Center Mainfranken, University Hospital Würzburg](https://onco.cc/institutions/ccc-wuerzburg/)
- technologies: [Autologous CAR-T manufacturing, batch by batch](https://onco.cc/technologies/car-t-manufacturing-process/)

---
JSON: https://onco.cc/api/v1/entities/legend-biotech.json